Zarxio: How Channel Dynamics Will Limit the First U.S. Biosimilar
Drug Channels - March 10, 2015
Last week, the Food and Drug Administration (FDA) approved Zarxio, the first U.S. biosimilar. Zarxio, a provider-administered specialty drug, is a non-interchangeable version of Amgen’s Neupogen.
Mother Nature Axes 340B Hearing, But Written Testimony Survives
JD Supra - March 6, 2015
The U.S. House of Representatives Energy and Commerce Subcommittee on Health was scheduled to hold a hearing on March 5, 2015 – Examining the 340B Drug Pricing Program. But with another winter storm aimed at Washington, the hearing was cancelled. The cancellation came after witnesses had submitted their written testimony to subcommittee staff.
Report: Specialty drugs drive prescription spending jump
Associated Press - March 10, 2015
Prescription drugs spending jumped 13 percent last year, the biggest annual increase since 2003, according to the nation’s largest pharmacy benefits manager.
Safety of Herbal Supplements Pulls Prosecutors Together
New York Times - March 9, 2015
A group of attorneys general is expected to announce on Tuesday that they are forming a coalition to crack down on fraud and quality control issues in the herbal supplement industry.
Common Drug for Irregular Heartbeat Tied to Worse Outcomes
HealthDay News - March 4, 2015
Patients who take the heart rhythm drug digoxin may face a nearly 30 percent greater risk of death than patients not taking the drug, a review of prior research suggests.
Yes, we can build a better Medicare Part D appeals process
The Hill - March 9, 2015
Heeding bipartisan calls from Congress, recommendations from the Medicare Payment Advisory Commission (MedPAC), and alarming audit results, CMS proposes important policy changes to strengthen Part D appeals, the process that allows patients to challenge a Medicare prescription drug plan’s coverage decision.
Despite broad awareness, only half of doctors use prescription drug monitoring programs
Medical News Today - March 5, 2015
Survey finds that usability barriers dampen participation, yet nearly three-quarters who use state databases report prescribing fewer opioids.
New class of drugs dramatically increases healthy lifespan, mouse study suggests
ScienceDaily - March 9, 2015
Scientists have identified a new class of drugs that in animal models dramatically slows the aging process -- alleviating symptoms of frailty, improving cardiac function and extending a healthy lifespan.
Study Shows Who Benefits Most from Statins
Washington University in St. Louis - March 4, 2015
New research suggests that widely used statin therapy provides the most benefit to patients with the highest genetic risk of heart attack.
Contact,
Jan Tankersley
Senior Vice President, Marketing & Sales
Pharmaceutical Strategies Group (PSG)
Office: 972-943-7141
Email: JTankersley@PSGConsults.com
PSGNewsletter@PSGConsults.com
www.PSGConsults.com
 |
 |
 |